Innovation Series: Investors' Guide to Targeted Degraders

Targeted protein degradation is an emerging therapeutic modality that has experienced a dramatic upsurge in popularity among drug developers and investors over the past decade. Degraders sidestep several fundamental limitations faced by conventional drugs, and a new wave of biotech companies—mostly still private—are squarely focused on using degrader technology to make safer and more effective therapies. Building on the clinical and commercial successes of drugs like Revlimid and Faslodex, developers can now rationally design degraders to send virtually any desired target into the cellular rubbish bin.

In this report, we describe how different classes of degraders function, provide an overview of companies active in the space, and (perhaps most important) help untangle degrader-specific jargon for investors. With potential clinical proof-of-concept data expected for key degraders later this year, we believe now is an excellent time for investors to become acquainted with the landscape.

If you're a client and want to read the full report, including disclosures, you can log in and click on the Research tab.

Not a client and want to learn more? Reach out to an Oppenheimer Financial Professional.